Dr. Alexander is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 205-541-7371- Is this information wrong?
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Advanced Heart Failure and Transplant Cardiology, 2018 - 2019
- Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2014 - 2017
- Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
- Perelman School of Medicine at the University of PennsylvaniaClass of 2011
Certifications & Licensure
- HI State Medical License 2022 - 2026
- CA State Medical License 2018 - 2025
- MA State Medical License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 58 citationsHigh-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning.Grant Duffy, Paul P Cheng, Neal Yuan, Bryan He, Alan C Kwan
JAMA Cardiology. 2022-04-01 - 13 citationsAlmanac - Retrieval-Augmented Language Models for Clinical Medicine.Cyril Zakka, Rohan Shad, Akash Chaurasia, Alex R Dalal, Jennifer L Kim
NEJM AI. 2024-02-01 - 29 citationsPulling at the heart: COVID-19, race/ethnicity and ongoing disparities.Peter Chin-Hong, Kevin M. Alexander, Norrisa Haynes, Michelle A. Albert
Nature Reviews. Cardiology. 2020-07-27
Press Mentions
- BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29th, 2024
- Additional Data Showing Acoramidis Increases Serum Transthyretin Which Is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 30th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingMay 25th, 2024
Hospital Affiliations
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: